An interview with Wataru Akahata, CEO of VLP Therapeutics (VLPT) and VLPT Japan, has been featured in the latest issue of WIRED magazine and on its online edition. "Vaccine development is incredibly hard, but once realized, it can protect far more lives more affordably than surgery. That’s what makes it so vital," said Wataru Akahata
VLP Therapeutics Japan, Inc. (VLPT Japan), a Tokyo-based biotech company, announced on March 31 the initiation of a Phase 1 clinical trial in Japan for its COVID-19 vaccine (VLPCOV-U-01). VLPCOV-U-01 is a novel T-cell inducing mRNA vaccine designed to prevent the onset and progression of COVID‑19. Currently approved mRNA vaccines are based on humoral immunity,
VLP Therapeutics Japan, Inc. (VLPT Japan) researchers and their colleagues at the National Institutes of Biomedical Innovation, Health and Nutrition (NIBN) in Japan published a paper in iScience online reporting safety, immunogenicity, and optimal dosing of VLPCOV-02, a SARS-CoV-2 saRNA vaccine with modified 5-methylcytosine base. This research was supported by AMED under Grant Number JP21nf0101627.
Maryland, US-based biotech company VLP Therapeutics, Inc. (VLPT) announced today that it has been awarded a two-year grant of over US$ 2.8 million (about JPY 433 million) from the Gates Foundation to develop next-gen multi-stage malaria vaccines. As an additional site for this work, a portion of the budget will also be earmarked for VLPT
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Boston University and the National Institutes of Health (NIH) have demonstrated that incorporating a modified base known as 5-methylcytidine (5mC) into replicon-based self-amplifying RNA (saRNA) vaccines for COVID-19 can suppress innate immune responses that cause adverse reactions, while maintaining strong immunogenicity. This replicon platform technology is
Swedish-US partnership to develop predictive models that could transform personalized cancer treatment selection Gaithersburg, USA and LUND, Sweden, 11 November 2025 – Nygen Analytics AB, a pioneer in AI-powered single-cell analysis technology, announced today it has been awarded a 1 million SEK (~ $105,000) grant from Vinnova, Sweden's innovation agency, to develop AI-driven predictive models
VLP Therapeutics, Inc. (VLPT), Maryland, US-based biotech company, announced on August 27 the initiation of a Phase 1 clinical trial of VLPONC-01, a new cancer immunotherapy, in collaboration with Stanford Medicine. The trial (NCT06736379) is being conducted at Stanford Health Care with the primary objectives of assessing the safety of cancer immunotherapy and identifying
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Stanford University School of Medicine posted on August 11 a preprint "Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity" on bioRxiv, a preprint server for biology. Note: Preprints are preliminary reports of work that have not been certified by
VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Stanford University and the University of North Carolina at Chapel Hill reported their findings online ahead of print in the Journal of Controlled Release, a peer-reviewed medical journal with an impact factor of 10.5 published by Elsevier. Stanford took the lead in this collaborative work. Title:
Maryland, US-based biotech company VLP Therapeutics, Inc. (VLPT) announced today that it has been awarded an investment totaling 885 million yen (about US$6 million) from the Global Health Innovative Technology (GHIT) Fund for a Phase I clinical trial of novel dengue virus-like-particle (VLP) vaccines. VLPT will share the funding (RFP-PD-2024-001) with its collaboration partners, Johns
